Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NRM0
UPID:
GTR9_HUMAN
Alternative names:
Glucose transporter type 9; Urate transporter
Alternative UPACC:
Q9NRM0; Q0VGC4; Q4W5D1; Q8WV30; Q96P00
Background:
Solute carrier family 2, facilitated glucose transporter member 9 (SLC2A9), also known as Glucose transporter type 9 and Urate transporter, plays a pivotal role in urate reabsorption in proximal renal tubules. It exhibits a high-capacity for urate transport, significantly outpacing its glucose transport activity. Additionally, SLC2A9 has a minor role in transporting fructose and adenine, but not galactose or other nucleobases.
Therapeutic significance:
SLC2A9's dysfunction is linked to Hypouricemia renal 2, a disorder marked by impaired uric acid reabsorption leading to high urinary urate excretion. This condition can result in exercise-induced acute renal failure, chronic renal dysfunction, and nephrolithiasis. Understanding the role of SLC2A9 could open doors to potential therapeutic strategies for managing these renal complications.